Last reviewed · How we verify
RGN-259
RGN-259 is a stem cell therapy that aims to promote retinal regeneration.
RGN-259 is a stem cell therapy that aims to promote retinal regeneration. Used for Treatment of retinitis pigmentosa.
At a glance
| Generic name | RGN-259 |
|---|---|
| Also known as | Tβ4, Thymosin Beta 4, Timbetasin |
| Sponsor | ReGenTree, LLC |
| Drug class | stem cell therapy |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
RGN-259 uses a patient's own stem cells to generate new retinal cells, which can potentially replace damaged or diseased cells in the retina. This approach has shown promise in preclinical studies for treating various retinal diseases.
Approved indications
- Treatment of retinitis pigmentosa
Common side effects
- Unknown
Key clinical trials
- Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 (PHASE3)
- Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1 (PHASE3)
- Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 (PHASE3)
- Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 (PHASE3)
- Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 (PHASE2, PHASE3)
- Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye (PHASE2)
- Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye (PHASE2)
- A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RGN-259 CI brief — competitive landscape report
- RGN-259 updates RSS · CI watch RSS
- ReGenTree, LLC portfolio CI